12.01.07
Indication: Cholesterol-lowering
Source: Alternative Therapies in Health & Medicine, November/December 2007;13(6):44-8.
Research:
Preliminary studies have suggested that both citrus flavonoids and palm tocotrienols reduce cholesterol levels in laboratory animals. To test this theory, researchers examined the effect of these nutrients in combination on blood levels of cholesterol and related cardiovascular disease risk factors. Two open-label studies and one double-blind study were initiated. Three groups (n=10, n=10, n=120) of hypercholesterolemic men and women (cholesterol levels >230 mg/dL) between the ages of 19 and 65 years were recruited. Subjects were randomized to consume either 270 mg citrus flavonoids plus 30 mg tocotrienols (Sytrinol) or placebo (P) daily for a period of 4 weeks (group 1 [G1] and group 2 [G2]) or 12 weeks (group 3 [G3]). Measurements of fasting levels of blood cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides were made at baseline and 4 weeks (all groups), as well as at 8 weeks and 12 weeks (G3).
Results:
Daily treatment with Sytrinol significantly improved cardiovascular parameters compared to placebo in all groups. Significant reductions were shown in total cholesterol (20%-30%), LDL (19%-27%), apolipoprotein B (21%) and triglycerides (24%-34%).
Source: Alternative Therapies in Health & Medicine, November/December 2007;13(6):44-8.
Research:
Preliminary studies have suggested that both citrus flavonoids and palm tocotrienols reduce cholesterol levels in laboratory animals. To test this theory, researchers examined the effect of these nutrients in combination on blood levels of cholesterol and related cardiovascular disease risk factors. Two open-label studies and one double-blind study were initiated. Three groups (n=10, n=10, n=120) of hypercholesterolemic men and women (cholesterol levels >230 mg/dL) between the ages of 19 and 65 years were recruited. Subjects were randomized to consume either 270 mg citrus flavonoids plus 30 mg tocotrienols (Sytrinol) or placebo (P) daily for a period of 4 weeks (group 1 [G1] and group 2 [G2]) or 12 weeks (group 3 [G3]). Measurements of fasting levels of blood cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides were made at baseline and 4 weeks (all groups), as well as at 8 weeks and 12 weeks (G3).
Results:
Daily treatment with Sytrinol significantly improved cardiovascular parameters compared to placebo in all groups. Significant reductions were shown in total cholesterol (20%-30%), LDL (19%-27%), apolipoprotein B (21%) and triglycerides (24%-34%).